Reporting owner · CIK 0001859453

Fordyce Marshall

Visual SEC Form 4 history across 1 companies, 14 transactions and 5 filings.

PRESPRESIDENT AND CEOVera Therapeutics, Inc.
Open-market mix
Latest filingSep 04, 2026, 08:15 PM
Filings5Form 4 records
Buying$00 purchases
Selling$1.2M4 sales
Net value−$1.2MBuys minus sells
Companies13 securities
Most recentSep 02, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Dec 233Feb 25Feb 261Sep 26

Net value flow

Buys minus sells

Dec 23
$0
Feb 25
−$546.9K
Feb 26
$0
Sep 26
−$649.6K

Transaction texture

Ownership and ticket size

Average P/S size$299.1K
Median P/S size$257.9K
Direct14
Indirect0
Sep 02, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Delayed Filingfiling-context1Derivative Transactionfiling-context4Direct Ownershipfiling-context11Large Holdings Increaseholdings4Repeat Sellerpattern210b5-1 Detectedfiling-context3

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Vera Therapeutics, Inc. on Sep 02, 2026 valued at $649,642.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Vera Therapeutics, Inc. on Sep 02, 2026 valued at $649,642.

Review SEC filing

Associated companies

Visual map of known reporting history

VERAVera Therapeutics, Inc.14 transactions · latest Sep 04, 2026, 08:15 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
VERAFordyce Marshall
PRES
exercise10b5-118.5k$0M
Derivative Transaction Direct Ownership 10b5-1 Detected
0.0%09/0409/02
VERAFordyce Marshall
PRES
sale10b5-118.5k-$64.9MS
Direct Ownership Large Sale 10b5-1 Detected
0.0%09/0409/02
VERAFordyce Marshall
PRES
exercise10b5-118.5k$5.35MM
Direct Ownership 10b5-1 Detected
0.0%09/0409/02
VERAFordyce Marshall
PRES
grant137k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
−16.8%02/0702/04
VERAFordyce Marshall
PRES
grant68.8k$0A
Direct Ownership Large Holdings Increase
−16.8%02/0702/04
VERAFordyce Marshall
PRES
sale10b5-11.10k-$3.11MS
Direct Ownership Repeat Seller 10b5-1 Detected
—02/27/202502/26/2025
VERAFordyce Marshall
PRES
sale10b5-17.97k-$21.9MS
Direct Ownership Repeat Seller 10b5-1 Detected
—02/27/202502/26/2025
VERAFordyce Marshall
PRES
sale10b5-110.6k-$29.6MS
Delayed Filing Direct Ownership 10b5-1 Detected
—02/27/202502/21/2025
VERAFordyce Marshall
PRES
grant161k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—02/20/202502/18/2025
VERAFordyce Marshall
PRES
grant80.7k$0A
Direct Ownership Large Holdings Increase
—02/20/202502/18/2025

Fordyce Marshall Insider Activity FAQ

SEC Form 4 context

Who is Fordyce Marshall?

Fordyce Marshall is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001859453.

Which companies has Fordyce Marshall reported transactions for?

Vera Therapeutics, Inc.

When was Fordyce Marshall's latest insider buy?

No open-market insider purchase is available for this period.

When was Fordyce Marshall's latest insider sale?

sale at Vera Therapeutics, Inc. on Sep 02, 2026 valued at $649,642.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.